Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

References

• Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127(1):P1–P65. doi:10.1016/j.ophtha.2019.09.024
   PubMed Web of Science ®Google Scholar
• Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern®. Ophthalmology. 2020;127(1):P66–P145. doi:10.1016/j.ophtha.2019.09.025
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. Lucentis® (ranibizumab injection) for intravitreal injection. Available from: https://www.gene.com/download/pdf/lucentis_prescribing.pdf. Accessed February 5, 2020.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Eylea® (aflibercept) injection, for intravitreal use. Available from: https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf. Accessed February 5, 2020.
   Google Scholar
• Novartis Pharmaceuticals Corporation. Beovu® (brolucizumab-dbll) injection, for intravitreal use. Available from: https://www.novartis.us/sites/www.novartis.us/files/beovu.pdf. Accessed July 2, 2020.
   Google Scholar
• Genentech, Inc. Avastin® (bevacizumab) injection, for intravenous use. Available from: https://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed February 9, 2020.
   Google Scholar
• Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMoa1414264
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022
   PubMed Web of Science ®Google Scholar
• Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99(2):141–146. doi:10.1136/bjophthalmol-2014-305149
   PubMed Web of Science ®Google Scholar
• Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review. Ophthalmology. 2016;123(1):70–77.e1. doi:10.1016/j.ophtha.2015.09.002
   PubMed Web of Science ®Google Scholar
• Sarwar S, Clearfield E, Soliman MK, et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2016;2016(2):CD011346. doi:10.1002/14651858.CD011346.pub2
   Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc. 2008;6:12. doi:10.1186/1478-7547-6-12
   PubMedGoogle Scholar
• Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–896. doi:10.1001/jamaophthalmol.2016.1669
   PubMed Web of Science ®Google Scholar
• Holekamp N, Duff SB, Rajput Y, Garmo V. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year protocol T data. J Med Econ. 2019;23(3):287–296. doi:10.1080/13696998.2019.1666855
   Web of Science ®Google Scholar
• Kiss S, Malangone-Monaco E, Wilson K, et al. Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema. J Manag Care Spec Pharm. 2020;26(3):253–266. doi:10.18553/jmcp.2020.19245
   Web of Science ®Google Scholar
• Parchman ML, Zeber JE, Palmer RF. Participatory decision making, patient activation, medication adherence, and intermediate clinical outcomes in type 2 diabetes: a STARNet study. Ann Fam Med. 2010;8(5):410–417. doi:10.1370/afm.1161
   PubMed Web of Science ®Google Scholar
• Lindhiem O, Bennett CB, Trentacosta CJ, McLear C. Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis. Clin Psychol Rev. 2014;34(6):506–517. doi:10.1016/j.cpr.2014.06.002
   PubMed Web of Science ®Google Scholar
• Shingler SL, Bennett BM, Cramer JA, Towse A, Twelves C, Lloyd AJ. Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin. 2014;30(11):2329–2341. doi:10.1185/03007995.2014.952715
   PubMed Web of Science ®Google Scholar
• Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530–1533. doi:10.1136/bmj.320.7248.1530
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Bhargava JS, Patel B, Foss AJE, Avery AJ, King AJ. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. Invest Ophthalmol Vis Sci. 2006;47(7):2885–2888. doi:10.1167/iovs.05-1244
   PubMed Web of Science ®Google Scholar
• Bhargava JS, Bhan-Bhargava A, Foss AJE, King AJ. Views of glaucoma patients on provision of follow-up care; an assessment of patient preferences by conjoint analysis. Br J Ophthalmol. 2008;92(12):1601–1605. doi:10.1136/bjo.2008.140483
   Web of Science ®Google Scholar
• Ross MA, Avery AJ, Foss AJE. Views of older people on cataract surgery options: an assessment of preferences by conjoint analysis. Qual Saf Health Care. 2003;12(1):13–17. doi:10.1136/qhc.12.1.13
   Google Scholar
• Wirostko B, Beusterien K, Grinspan J, et al. Patient preferences in the treatment of diabetic retinopathy. Patient Prefer Adherence. 2011;5:229–237. doi:10.2147/PPA.S11972
   PubMed Web of Science ®Google Scholar
• Baxter JM, Fotheringham AJ, Foss AJE. Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye. 2016;30(5):698–704. doi:10.1038/eye.2016.18
   PubMed Web of Science ®Google Scholar
• QuestionPro, Inc. Conjoint analysis for market research. Available from: https://www.surveyanalytics.com/conjoint/index.html. Accessed May 1, 2020.
   Google Scholar
• QuestionPro, Inc. Conjoint analysis: definition, example, types, algorithm and model. Available from: https://www.questionpro.com/blog/what-is-conjoint-analysis/. Accessed May 1, 2020.
   Google Scholar
• Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T. Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology. 2016;123(4):876–883. doi:10.1016/j.ophtha.2015.12.001
   PubMed Web of Science ®Google Scholar
• Mason L, Crosson JN, Mason JO, McGwin G. Patient preferences with regard to laser versus intravitreal injections in the treatment of diabetic macular edema. J Ophthalmol. 2017;2017:7398470. doi:10.1155/2017/7398470
   Web of Science ®Google Scholar
• Jager RD, Aiello LP, Patel SC, Cunningham ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676–698. doi:10.1097/00006982-200410000-00002
   PubMed Web of Science ®Google Scholar
• Freund KB, Korobelnik J-F, Devenyi R, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases. Retina. 2015;35(8):1489–1506. doi:10.1097/IAE.0000000000000627
   PubMed Web of Science ®Google Scholar